Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Treating to target with etanercept in rheumatoid arthritis: cost-effectiveness of dose reductions when remission is achieved.

Kobelt, Gisela LU (2014) In Value in Health 17(5). p.537-544
Abstract
Current management of rheumatoid arthritis (RA) focuses on inducing remission as early as possible to avoid lasting joint damage, and maintenance of remission has become important. A 12-month clinical trial in 834 patients with moderate RA investigated whether etanercept 50 mg/wk could be reduced to half dose or discontinued in patients who achieved low disease activity after 36 weeks.
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Value in Health
volume
17
issue
5
pages
537 - 544
publisher
Wiley-Blackwell
external identifiers
  • pmid:25128046
  • wos:000341084700007
  • scopus:84906273443
  • pmid:25128046
ISSN
1098-3015
DOI
10.1016/j.jval.2014.04.005
language
English
LU publication?
yes
id
1d31cc88-c168-4275-a800-4fb2e7fff73f (old id 4614514)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25128046?dopt=Abstract
date added to LUP
2016-04-01 11:13:13
date last changed
2022-03-12 20:43:51
@article{1d31cc88-c168-4275-a800-4fb2e7fff73f,
  abstract     = {{Current management of rheumatoid arthritis (RA) focuses on inducing remission as early as possible to avoid lasting joint damage, and maintenance of remission has become important. A 12-month clinical trial in 834 patients with moderate RA investigated whether etanercept 50 mg/wk could be reduced to half dose or discontinued in patients who achieved low disease activity after 36 weeks.}},
  author       = {{Kobelt, Gisela}},
  issn         = {{1098-3015}},
  language     = {{eng}},
  number       = {{5}},
  pages        = {{537--544}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{Value in Health}},
  title        = {{Treating to target with etanercept in rheumatoid arthritis: cost-effectiveness of dose reductions when remission is achieved.}},
  url          = {{http://dx.doi.org/10.1016/j.jval.2014.04.005}},
  doi          = {{10.1016/j.jval.2014.04.005}},
  volume       = {{17}},
  year         = {{2014}},
}